DURECT Corporation Provides Corporate Update
DURECT Corporation (DRRX)
Last durect corporation earnings: 3/3 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
durect.com/investors
Company Research
Source: PR Newswire
CUPERTINO, Calif., Jan. 7, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) has refined and focused its clinical development strategy for DUR-928, the lead product candidate in its Epigenetic Regulator Program, to prioritize indications with unmet medical needs where we expect to be able to generate near-term data with the potential to create significant commercial and partnering value. The new DUR-928 clinical development strategy is:1. Accelerate DUR-928 clinical trial in non-alcoholic steatohepatitis (NASH) patients. DURECT previously announced that it would be initiating a new clinical trial of orally-administered DUR-928 in NASH patients in the first half of 2019, and is now updating that guidance to indicate that the Company expects to begin enrolling patients in Q1 2019. This will be an open-label, Phase 1b study conducted in the U.S. to evaluate safety, pharmacokinetics and signals of biological activity of DUR-928 in patients with NASH. Patients will be administered D
Show less
Read more
Impact Snapshot
Event Time:
DRRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DRRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DRRX alerts
High impacting DURECT Corporation news events
Weekly update
A roundup of the hottest topics
DRRX
News
- DURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business UpdatePR Newswire
- DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated HepatitisPR Newswire
- DURECT Corporation (NASDAQ:DRRX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- DURECT Co. (NASDAQ: DRRX) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $5.00 price target on the stock.MarketBeat
- DURECT Co. (NASDAQ: DRRX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
DRRX
Earnings
- 3/27/24 - Beat
DRRX
Sec Filings
- 4/30/24 - Form 8-K
- 3/28/24 - Form 424B5
- 3/28/24 - Form 10-K
- DRRX's page on the SEC website